Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer Inc (NYSE:PFE) shares are moving lower Wednesday alongside several pharmaceutical giants after President Donald Trump ...

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...